Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2

被引：6
|
作者：
Piccart, M. [1 ]
Hortobagyi, G. N. [2 ]
Campone, M. [3 ]
Pritchard, K. I. [4 ,5 ]
Noguchi, S. [6 ]
Rugo, H. [7 ]
Gnant, M. [8 ]
Feng, W. [7 ,9 ]
Taran, T. [9 ]
Baselga, J. [10 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Ctr Rech Canc, Inst Canc Ouest Rene Gauducheau, St Herblain, France
[4] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Osaka Univ, Sch Med, Suita, Osaka 565, Japan
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria
[9] Novartis Oncol, E Hanover, NJ USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)00221-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1LBA
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [21] Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
    J. Thaddeus Beck
    Gabriel N. Hortobagyi
    Mario Campone
    Fabienne Lebrun
    Ines Deleu
    Hope S. Rugo
    Barbara Pistilli
    Norikazu Masuda
    Lowell Hart
    Bohuslav Melichar
    Shaker Dakhil
    Matthias Geberth
    Martina Nunzi
    Daniel Y. C. Heng
    Thomas Brechenmacher
    Mona El-Hashimy
    Shyanne Douma
    Francois Ringeisen
    Martine Piccart
    [J]. Breast Cancer Research and Treatment, 2014, 143 : 459 - 467
  • [22] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    [J]. ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [23] Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib plus fulvestrant vs everolimus plus exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)
    Ciruelos, E. M.
    Delea, T.
    Moynahan, A.
    Mayer, I.
    Park, J.
    Chandiwana, D.
    Ridolfi, A.
    Lorenzo, I.
    Rugo, H. S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S74 - S74
  • [24] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Puttawibul, Puttisak
    Srimuninnimit, Vichien
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Noh, Woo-Chul
    Nakayama, Takahiro
    Ohno, Shinji
    Rai, Yoshiaki
    Park, Byeong-Woo
    Panneerselvam, Ashok
    El-Hashimy, Mona
    Taran, Tetiana
    Sahmoud, Tarek
    Ito, Yoshinori
    [J]. BREAST CANCER, 2014, 21 (06) : 703 - 714
  • [25] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De Laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    El-Hashimy, Mona
    Sellami, Dalila
    Baselga, Jose
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
  • [26] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [27] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    [J]. CANCER RESEARCH, 2017, 77
  • [28] Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
    Hortobagyi, Gabriel N.
    [J]. NEOPLASIA, 2015, 17 (03): : 279 - 288
  • [29] Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR plus ) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review
    Zhu, Linhui
    Wang, Mengmeng
    Luo, Xin
    Li, Huan
    Shan, Han
    Du, Qiong
    Zhai, Qing
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
  • [30] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Cottu, Paul
    De Laurentiis, Michelino
    Marchetti, Paolo
    Coltelli, Luigi
    Califaretti, Nadia
    Debled, Marc
    Patil, Shekar
    Evron, Ella
    Duhoux, Francois
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Bofill, Javier Salvador
    [J]. CANCER RESEARCH, 2021, 81 (04)
12345